

10/551901

Docket No. 277987US0PCT

IC20 Rec'd 10/04/05 04 OCT 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hiroshi MIURA, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/JP04/06141

GAU:

FILED: Herewith

EXAMINER:

FOR: COMPOSITION CONTAINING MEDICINE EXTREMELY SLIGHTLY SOLUBLE IN WATER AND METHOD FOR PREPARATION THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION


- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

277987US0PCT

SERIAL NO.

10/551901  
Based on PCT/JPO/06141

## LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Hiroshi MIURA, et al.

FILING DATE

Herewith

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO	2002-345940	12/03/02	JP (English abstract only)		NO
	AP	61-227520	10/09/86	JP (English abstract only)		NO
	AQ	6-0404714	02/15/94	JP (English abstract only)		NO
	AR	2000-198776	07/18/00	JP (English abstract only & equivalent of US 2002/0123496 & US 6348468)		NO
	AS	02/051381	07/04/02	WO		NO
	AT	02/20624	03/14/02	WO		NO
	AU	2002/060411	08/08/02	WO (equivalent of US 2003/041602 & US 2004/022861)		
	AV					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AW	David D. Hile et al., Active growth delivery from poly (D, L-lactide-co-glycolide) foams prepared in supercritical CO <sub>2</sub> , Journal of Controlled Release, Vol. 66, Pages 177 to 185, 2000.
	AX	Petra Sencar-Bozic et al., Improvement of nifedipine dissolution characteristics using supercritical CO <sub>2</sub> , International Journal of Pharmaceutics, Vol. 148, Pages 123 to 130, 1997
	AY	
	AZ	

☐ Additional References sheet(s) attached

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.